PAREXEL Biopharmaceutical R&D Statistical Sourcebook 2011/2012 Buy on Amazon

https://www.ebooknetworking.net/books_detail-1882615964.html

PAREXEL Biopharmaceutical R&D Statistical Sourcebook 2011/2012

390.63 425.00 USD
Buy New on Amazon 🇺🇸 Buy Used — $984.37

Usually ships in 24 hours

Book Details

ISBN / ASIN1882615964
ISBN-139781882615964
AvailabilityUsually ships in 24 hours
Sales Rank2,346,421
MarketplaceUnited States  🇺🇸

Description

The PAREXEL Biopharmaceutical R&D Statistical Sourcebook 2011/2012 is the leading resource for statistics, trends, and proprietary market intelligence and analysis on the biopharmaceutical industry. Supported by thousands of graphs, illustrations, and analysis, the Sourcebook provides the latest intelligence on every aspect of biopharmaceutical development from product discovery, to R&D performance and productivity, to time-to-market trends. With key analysis and contributions from leading consultancies and experts, the Sourcebook provides real-world data and analysis, including: * New proprietary analysis on US clinical trial starts, segmented by therapeutic category, as well as overall active clinical trials. * Emerging data on worldwide and company-specific R&D pipelines and product launch trends. * An all-new and comprehensive analysis of clinical research off-shoring revealing which pharma companies are now locating their new clinical trials overseas. * New analysis on emerging trends in pharma and biotech licensing deals and other partnerships critical to industry's efforts. * Drug approval statistics compiled from FDA, EMEA, and other regulatory agencies. * New global R&D spending trends and other international R&D data from key markets. * International statistics on drug development output. * And much more! Plus, NEW in the 2011/2012 edition: * All-new analyses and actual/projected metrics on the biosimilars market. * A series of new "dashboards" on costs by phase of development, R&D attrition rates, product development times, and other areas. * Forecasting models on biopharma sales, R&D spending, the pharma/biotech markets, and other meaningful industry metrics. * New analyses on patient recruitment into clinical trials. The PAREXEL Biopharmaceutical R&D Statistical Sourcebook 2011/2012 is a must-have resource for the drug development industry. It is an invaluable resource for executives and managers working in the pharma and biotech industries. The Sourcebook puts real-world data sets at your fingertips for presentations, reports, business development efforts, strategic meetings, and critical decision-making analyses.
Donate to EbookNetworking
Prev
Next